von Willebrand disease: Clinical and laboratory lessons learned from the large von Willebrand disease studies

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  James, Paula D ^a   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN; DESMOPRESSIN; ESTROGEN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BLOOD TRANSFUSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; HORMONE SUBSTITUTION; HUMAN; MISSENSE MUTATION; MOLECULAR CLONING; ORAL CONTRACEPTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; SKIN BLEEDING; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE;

CLONING, MOLECULAR; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; GENETIC TESTING; HEMORRHAGE; HEMOSTATICS; HUMANS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84859940652     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23142     Document Type: Article

References (84)

1. von Willebrand EA. Hereditar pseudohemofili. Finska Lakaresallskapets Handlingar 1926; 67: 87-112.
2. Nilsson IM, Blomback M, Jorpes E, et al. Von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Med Scand 1957; 159: 179-188.
3. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor v) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Investig 1971; 50: 244-254.
4. Ruggeri ZM, Zimmerman TS. Classification of variant von Willebrand's disease subtypes by analysis of functional characteristics and multimeric composition of factor viii/von willebrand factor. Ann N Y Acad Sci 1981; 370: 205-209.
5. Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (VWF): Isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 1401-1406.
6. Sadler JE, Shelton-Inloes BB, Sorace JM, et al. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci USA 1985; 82: 6394-6398.
7. Lynch DC, Zimmerman TS, Collins CJ, et al. Molecular cloning of cDNA for human von Willebrand factor: Authentication by a new method. Cell 1985; 41: 49-56.
8. Verweij CL, de Vries CJ, Distel B, et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res 1985; 13: 4699-4717.
9. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-2114.
10. Mannucci PM. Desmopressin (DDAVP) and factor VIII: The tale as viewed from Milan (and Malmo). J Thromb Haemost 2003; 1: 1538-7933.
11. Pottinger BE, Read RC, Paleolog EM, et al. Von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 387-394.
12. Prentice CRM, Forbes SS. Rise of factor FVIII after exercise and adrenaline infusion measured by immunological and biological techniques. Thromb Res 1972; 1: 493-506.
13. Vischer UM, Wollheim CB. Epinephrine induces von Willebrand factor release from cultured endothelial cells: Involvement of cyclic AMP-dependent signaling in exocytosis. Thromb Haemost 1997; 77: 1182-1188.
14. Liu L, Wang X, Lin Z, Wu H. Elevated plasma levels of VWF:Ag in hyperthyroidism are mediated through beta-adrenergic receptors. Endocrine Res 1993; 19: 123-133.
15. Dalton RG, Dewar MS, Savidge GF, et al. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1987; 1: 1007-1009.
16. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-1170.
17. Stirling Y, Woolf L, North WR, et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182.
18. May M, Lawlor DA, Patel R, et al. Associations of von Willebrand factor, fibrin d-dimer and tissue plasminogen activator with incident coronary heart disease: British women's heart and health cohort study. Eur J Cardiovasc Prevent Rehabil 2007; 14: 638-645.
19. Kumari M, Marmot M, Brunner E. Social determinants of von Willebrand factor: The Whitehall II study. Arteriosclerosis Thromb Vasc Biol 2000; 20: 1842-1847.
20. Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999; 82: 585-591.
21. Orstavik KH. Genetics of plasma concentration of von willebrand factor. Folia Haematol (Leipzig, Germany: 1928) 1990; 117: 527-531.
22. de Lange M, Snieder H, Ariëns RA, et al. The genetics of haemostasis: A twin study. Lancet 2001; 357: 101-105.
23. de Lange M, de Geus EJC, Kluft C, et al. Genetic influences on fibrinogen, tissue plasminogen activator-antigen and von Willebrand factor in males and females. Thromb Haemost 2006; 95: 414-419.
24. Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: From the patient to the gene. Inserm network on molecular abnormalities in von willebrand disease. Thromb Haemost 1997; 78: 451-456.
25. Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von willebrand disease. Proc Natl Acad Sci USA 1991; 88: 4761-4765.
26. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-4430.
27. O'Brien LA, Sutherland JJ, Weaver DF, Lillicrap D. Theoretical structural explanation for group I and group II, type 2A von Willebrand disease mutations. J Thromb Haemost 2005; 3: 796-797.
28. Hillery CA, Mancuso DJ, Evan SJ, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin-but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91: 1572-1581.
29. James PD, Notley C, Hegadorn C, et al. Challenges in defining type 2M von Willebrand disease: Results from a Canadian cohort study. J Thromb Haemost 2007; 5: 1914-1922.
30. Ruggeri ZM. Type IIb von willebrand disease: A paradox explains how von Willebrand factor works. J Thromb Haemost 2004; 2: 2-6.
31. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: A cohort study of 67 patients. Blood 2008; 113: 526-534.
32. Murray EW, Giles AR, Lillicrap D. Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease. Am J Hum Genet 1992; 50: 199-207.
33. Russell SD, Roth GJ. Pseudo-von Willebrand disease: A mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 1993; 81: 1787-1791.
34. Takahashi H, Murata M, Moriki T, et al. Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease. Blood 1995; 85: 727-733.
35. Matsubara Y, Murata M, Sugita K, Ikeda Y. Identification of a novel point mutation in platelet glycoprotein Ib alpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. J Thromb Haemost 2003; 1: 2198-2205.
36. Othman M, Notley C, Lavender FL, et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIba gene resulting in platelet-type von Willebrand disease. Blood 2005; 105: 4330-4336.
37. Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Ib alpha and its complex with von Willebrand factor A1 domain. Science 2002; 297: 1176-1179.
38. Sadler JE. Biomedicine. Contact-How platelets touch von Willebrand factor. Science 2002; 297: 1128-1129.
39. Ribba AS, Loisel I, Lavergne JM, et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001; 86: 848-854.
40. Riddell A, Gomez K, Millar C, et al. Characterization of W1745C and S1783A, two novel collagen binding defects in the A3 domain of von Willebrand factor. Blood 2008; 114: 3489-3496.
41. Flood VH, Lederman CA, Wren JS, et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 2010; 8: 1431-1433.
42. Mazurier C. Von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992; 67: 391-396.
43. Mazurier C, Hilbert L. Type 2N von Willebrand disease. Curr Hematol Rep 2005; 4: 350-358.
44. Golder M, Pruss CM, Hegadorn C, et al. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions. Blood 2010; 115: 4862-4869.
45. Pruss CM, Golder M, Hegadorn C, et al. The impact of von Willebrand factor sequence changes that affect ADAMTS13-mediated cleavage in the von Willebrand factor knock-out mouse model. J Thromb Haemost 2009; 7 (s2): 11.
46. Eikenboom JC. Congenital von Willebrand disease type 3: Clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001; 14: 365-379.
47. Ngo KY, Glotz VT, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von willebrand disease. Proc Natl Acad Sci USA 1988; 85: 2753-2757.
48. Shelton-Inloes BB, Chehab FF, Mannucci PM, et al. Gene deletions correlate with the development of alloantibodies in von willebrand disease. J Clin Invest 1987; 79: 1459-1465.
49. Baronciani L, Cozzi G, Canciani MT, et al. Molecular defects in type 3 von willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 264-270.
50. Sutherland MS, Keeney S, Bolton-Maggs PHB, et al. The mutation spectrum associated with type 3 von Willebrand disease in a cohort of patients from the North West of England. Haemophilia 2009; 15: 1048-1057.
51. Baronciani L, Federici AB, Cozzi G, et al. Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von willebrand factor in patients with type 3 von Willebrand disease. Haemophilia 2008; 14: 549-555.
52. Sutherland MS, Cumming AM, Bowman M, et al. A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood 2009; 114: 1091-1098.
53. Schneppenheim R, Castaman G, Federici AB, et al. A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. J Thromb Haemost 2007; 5: 722-728.
54. Mohlke KL, Ginsburg D. Von Willebrand disease and quantitative variation in von Willebrand factor. J Lab Clin Med 1997; 130: 252-261.
55. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109: 145-154.
56. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Blood 2007; 109: 112-121.
57. Cumming A, Grundy P, Keeney S, et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-641.
58. Bellissimo DB, Christopherson PA, Flood VH, et al. Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood 2011. [Epub ahead of print].
59. O'Brien LA, James PD, Othman M, et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003; 102: 549-557.
60. Pruss CM, Golder M, Bryant A, et al. Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood 2011; 117: 4358-4366.
61. Schneppenheim R, Federici AB, Budde U, et al. Von Willebrand disease type 2M "Vicenza" in Italian and German patients: Identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000; 83: 136-140.
62. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002; 99: 180-184.
63. Gézsi A, Budde U, Deák I, et al. Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza. J Thromb Haemost 2010; 8: 1273-1280.
64. Hickson N, Hampshire D, Winship P, et al. Von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor FVIII levels. J Thromb Haemost 2010; 8: 1986-1993.
65. Othman M, Chirinian Y, Brown C, et al. Functional characterization of a 13 bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 2010; 116: 3645-3652.
66. Wang J-W, Groeneveld DJ, Cosemans G, et al. Biogenesis of Weibel-Palade bodies in von Willebrand disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation. Haematologica 2011. [Epub ahead of print].
67. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111: 4979-4985.
68. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 3344-3351.
69. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-1695.
70. Smith NL, Chen MH, Dehghan A, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The charge (cohorts for heart and aging research in genome epidemiology) consortium. Circulation 2010; 121: 1382-1392.
71. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H (O) structures. J Biol Chem 1992; 267: 8723-8731.
72. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-3545.
73. Campos M, Sun W, Yu F, et al. Genetic determinants of plasma von Willebrand factor antigen levels: A target gene SNP and haplotype analysis of ARIC cohort. Blood 2011; 117: 5224-5230.
74. Zabaneh D, Gaunt TR, Kumari M, et al. Genetic variants associated with von Willebrand factor levels in healthy men and women identified using the HumanCVD beadchip. Ann Hum Genet 2011; 75: 456-467.
75. Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report (USA). Haemophilia 2008; 14: 171-232.
76. Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: Clinical or research tools? Haemophilia 2008; 14:415-422.
77. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von willebrand disease: An international, multicenter study. J Thromb Haemost 2005; 3: 2619-2626.
78. Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost 2007; 5: 157-166.
79. Biss TT, Blanchette VS, Clark DS. Quantitation of bleeding symptoms in children with von Willebrand disease: Use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010; 8: 950-956.
80. Budde U, Schneppenheim R, Eikenboom J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 6: 762-771.
81. Sadler JE. Von Willebrand disease type 1: A diagnosis in search of a disease. Blood 2003; 101: 2089-2093.
82. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-459.
83. Werner EJ, Broxson EH, Tucker EL. Prevalence of von Willebrand disease in children: A multiethnic study. J Pediatr 1993; 123: 893-898.
84. Turecek PL, Schrenk G, Rottensteiner H, et al. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost 2010; 36: 510-521.